Assessing participants’ experiences with the COVID-19 symptom diary in a clinical trial

Assessing participants’ experiences with the COVID-19 symptom diary in a clinical trial

Abstract During a phase 2/3 study of twice-daily nirmatrelvir 300 mg coadministered with ritonavir 100 mg versus placebo for 5 days (NCT05011513), participants reported presence and severity of COVID-19 symptoms using a COVID-19 symptom diary in accordance with FDA guidance. Here, we aimed to evalua...

Full description

Saved in:
Bibliographic Details
Main Authors: T. Michelle Brown, Chisom Kanu, Magdalena Harrington
Format: Article
Language:English
Published: SpringerOpen 2025-08-01
Series:Journal of Patient-Reported Outcomes
Subjects:
COVID-19
SARS-CoV-2
Patient-reported outcomes
Exit interviews
Clinical trial
Online Access:https://doi.org/10.1186/s41687-025-00901-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s41687-025-00901-5

Similar Items